Anlon Healthcare manufactures high-quality Pharmaceutical Bulk Drugs & Intermediates compliant with FDA, PMDA, KFDA, cGMP & WHO-GMP.
01 1Anlon Healthcare Ltd
02 1Amara Labs
03 1Keminntek Laboratories
04 1Morepen Laboratories
05 1Valence Labs
Anlon Healthcare manufactures high-quality Pharmaceutical Bulk Drugs & Intermediates compliant with FDA, PMDA, KFDA, cGMP & WHO-GMP.
2-[4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-...
CAS Number : 154477-55-1
End Use API :
End Use API : Fexofenadine Hydrochloride
About the Company : Anlon Healthcare is a research-focused pharmaceutical manufacturer based in Rajkot, specializing in bulk drugs and intermediates. The company’s products comply with international stan...
METHYL 2-(4-(4-4-(HYDROXYDIPHENYLMETHYL)-1- PIPERI...
CAS Number : 154477-55-1
End Use API :
End Use API : Fexofenadine Hydrochloride
About the Company : Amara Labs Pvt Ltd is a WHO-GMP certified manufacturing company wholly owned by a team of technocrats with working experience of more than 20 years in Multi-Nationals Companies like Myl...
2-[4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-...
CAS Number : CAS-154477-55-1
End Use API :
End Use API : Fexofenadine Hydrochloride
About the Company : Keminntek Laboratories is a Hyderabad (India) based Contract Research Organization in Pharmaceutical sector in specific Pharmaceutical Intermediates, Speciality Chemicals, Impurities an...
2-(4-(4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-...
CAS Number : 154477-55-1
End Use API :
End Use API : Fexofenadine Hydrochloride
About the Company : Morepen Laboratories Ltd.’ is 31 years old company. Went to public in 1993. Manufacturer and Exporter of complex and high margins molecules (APIs/Intermediates) for regulated markets ...
Methyl 2-(4-(4-(4-(hydroxydiphenylmethyl)piperidin...
CAS Number : 154477-55-1
End Use API :
End Use API : Fexofenadine Hydrochloride
About the Company : Valence has worked diligently to position itself as a top global manufacturer of high-quality APIs, driven by an unwavering commitment to product excellence. As we advance on this path,...
